PDCD1 and colorectal carcinoma: Microsatellite-stable colorectal cancers (MSS-CRC) demonstrated resistance to anti-PD-1/PD-L1 therapies, but ex vivo analyses indicated that combining atezolizumab with Tiragolumab partially restored immune reactivity in TILs (Thibaudin et al., 2022).